Oral Mucosa Remodeling Induced by Injecting New Cellular Treatment Factor (NCTF) and Human-derived Exosomes (ASCE & CellExosome).
Adel N., Kolenda J.
Laboratory Study, published in Plast Reconstr Surg Glob Open (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Plast Reconstr Surg Glob Open (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41959941
- DOI
- 10.1097/GOX.0000000000007587
Abstract (original English)
Exosomes mediate tissue regeneration by promoting angiogenesis, fibroblast activity, and extracellular matrix remodeling. New Cellular Treatment Factor (NCTF), cellular treatment factor solutions containing amino acids, vitamins, nucleotides, coenzymes, minerals, and hyaluronic acid, are used in regenerative medicine, but their combined effects with human-derived exosomes on the oral mucosa remain unclear. The aim of this study was to evaluate the histological and immunohistochemical changes in normal hamster oral mucosa following treatment with an NCTF solution enriched with 2 distinct human exosome formulations at different time points. Sixty-three male hamsters were randomized into 3 groups: saline-injected control, NCTF with cell-derived exosomes (CellExosome), and NCTF solution with adipose stem cell-derived exosomes (ASCEs). Injections were administered into the buccal mucosa, and tissues were harvested at baseline, day 3, and day 7. Hematoxylin-eosin, Masson trichrome, and Van Gieson staining were used to assess mucosal structure and collagen remodeling, whereas angiogenesis was quantified using CD34 immunohistochemistry. Both exosome-treated groups demonstrated progressive increases in fibroblast proliferation, collagen organization, and microvessel density from day 3 to day 7 compared with controls. The NCTF + CellExosome group consistently exhibited the most pronounce
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.